ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

17 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

06 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

28 Jul 2024 17:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

20 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Expansion of Leadership Team

22 May 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

02 May 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

11 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

25 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

07 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

01 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

24 Jan 2024 07:30:00 By Nasdaq GlobeNewswire